TY - JOUR
T1 - Androgen receptor in triple negative breast cancer
T2 - A potential target for the targetless subtype
AU - Gerratana, L.
AU - Basile, D.
AU - Buono, G.
AU - De Placido, S.
AU - Giuliano, M.
AU - Minichillo, S.
AU - Coinu, A.
AU - Martorana, F.
AU - De Santo, I.
AU - Del Mastro, L.
AU - De Laurentiis, M.
AU - Puglisi, F.
AU - Arpino, G.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Triple negative breast cancer (TNBC) represents the 15–20% of all breast cancers (BC) and is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a single disease, but it is rather an umbrella for different ontology-profiles such as basal like 1 and 2, mesenchymal, and the luminal androgen receptor (LAR). The LAR subtype is characterized by the expression of the Androgen Receptor (AR) and its downstream effects. Notwithstanding the role of the AR in several signaling pathways, its impact on a biological and clinical standpoint is still controversial. The LAR subtype has been associated with better prognosis, less chemotherapy responsiveness and lower pathologic complete response after neoadjuvant treatment. Clinical evidence suggests a role for anti-androgen therapies such as bicalutamide, enzalutamide and abiraterone, offering an interesting chemo-free alternative for chemo-unresponsive patients, and therefore potentially shifting current treatment strategies.
AB - Triple negative breast cancer (TNBC) represents the 15–20% of all breast cancers (BC) and is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a single disease, but it is rather an umbrella for different ontology-profiles such as basal like 1 and 2, mesenchymal, and the luminal androgen receptor (LAR). The LAR subtype is characterized by the expression of the Androgen Receptor (AR) and its downstream effects. Notwithstanding the role of the AR in several signaling pathways, its impact on a biological and clinical standpoint is still controversial. The LAR subtype has been associated with better prognosis, less chemotherapy responsiveness and lower pathologic complete response after neoadjuvant treatment. Clinical evidence suggests a role for anti-androgen therapies such as bicalutamide, enzalutamide and abiraterone, offering an interesting chemo-free alternative for chemo-unresponsive patients, and therefore potentially shifting current treatment strategies.
KW - Antiandrogen therapy
KW - Epithelial-to-Mesenchymal Transition
KW - Luminal androgen receptor positive
KW - Triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85048885009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048885009&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2018.06.005
DO - 10.1016/j.ctrv.2018.06.005
M3 - Review article
AN - SCOPUS:85048885009
VL - 68
SP - 102
EP - 110
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
ER -